查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1344292

药品给药市场：按给药途径、按应用划分：2023-2032 年全球机会分析与产业预测

Pharmaceutical Drug Delivery Market By Route of Administration, By Application : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 236 Pages | 商品交期: 2-3个工作天内

价格

药品输送市场预计到 2022 年将达到 14,987.2 亿美元，到 2032 年将达到 23,072.7 亿美元，2023 年至 2032 年的复合年增长率为 4.4%。Masu。

医药给药市场-IMG1

心血管疾病、糖尿病、癌症、呼吸系统疾病等慢性疾病的特征是需要长期药物治疗。 这些疾病需要定期用药来控制症状、减缓疾病进展并维持生活品质。 因此，对有效药物输送系统的需求不断增加，从而推动了市场的成长。 国际糖尿病联盟（IDF）估计，到2021年，大约四分之三的糖尿病成年人将生活在低收入和中等收入国家，西太平洋地区将有大约2.06亿人被诊断出患有糖尿病。

例如，2022 年 5 月，美国食品药物管理局 (FDA) 批准了 Mounjaro，一种治疗 2 型糖尿病的新型注射给药产品。 因此，糖尿病盛行率的增加导致了对治疗糖尿病非常有效的先进胰岛素输送系统的开发。 此外，心血管疾病、关节炎、神经退化性疾病和骨质疏鬆症等与年龄相关的疾病的盛行率不断增加，对有效的药物传递产生了巨大的需求。

例如，2023 年 1 月，全球製药业领先者百健 (Biogen) 的阿兹海默症治疗药物 LEQEMBI 获得美国食品药物管理局 (FDA) 批准。 LEQEMBI是一种单株抗体定向静脉给药药物，可有效治疗阿兹海默症。 因此，新的标靶药物递送和控释製剂的开发将进一步促进市场成长。 然而，严格的监管要求增加了新药物输送技术的时间、成本和复杂性，并可能抑制市场成长。 此外，与新药物输送研发相关的高成本对市场成长有负面影响。

同时，对先进药物输送系统的需求不断增长预计将为预测期内的市场成长创造利润丰厚的机会。 这是由于慢性病盛行率不断上升、治疗结果改善以及有利于先进药物输送系统开发的报销政策的存在。

目录

第1章简介

第 2 章执行摘要

第3章市场概述

  • 市场定义和范围
  • 主要发现
    • 影响因素
    • 主要投资机会
  • 波特五力分析
    • 供应商的议价能力
    • 买方的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争强度
  • 市场动态
    • 促进因素
      • 各种慢性疾病的增加
      • 药物传□□输系统的技术进步
    • 抑制因素
      • 严格的给药审批监理要求
    • 机会
      • 对先进输送系统的需求不断增加
  • 新冠肺炎 (COVID-19) 市场影响分析

第 4 章药物给药市场：依给药途径划分

  • 摘要
  • 口服给药
  • 鼻腔给药
  • 眼部药物输送
  • 局部给药
  • 其他药物输送

第5章药物给药市场：依应用

  • 摘要
  • 癌症
  • 糖尿病
  • 心血管疾病
  • 其他

第6章药物给药市场：依地区

  • 摘要
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 韩国
    • 其他亚太地区
  • 拉丁美洲/中东/非洲
    • 巴西
    • 沙乌地阿拉伯
    • 南非
    • 其他领域

第7章竞争态势

  • 简介
  • 关键成功策略
  • 10家主要公司的产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 2022 年主要公司的定位

第8章公司简介

  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Bayer AG
  • Cipla Ltd
  • Amgen Inc.
Product Code: A06102

According to a new report published by Allied Market Research, titled, "Pharmaceutical Drug Delivery Market," The pharmaceutical drug delivery market was valued at $1,498.72 billion in 2022, and is estimated to reach $2307.27 billion by 2032, growing at a CAGR of 4.4% from 2023 to 2032.

Pharmaceutical Drug Delivery Market - IMG1

Chronic diseases, such as cardiovascular disorders, diabetes, cancer, and respiratory diseases, are characterized by long-term medication treatment. These conditions require regular administration of drugs to control symptoms, slow disease progression, or maintain quality of life. This has increased the demand for effective drug delivery systems, thereby driving the market growth. According to International Diabetes Federation (IDF), in 2021, it was estimated that about 3 in 4 adults with diabetes live in low and middle-income countries and approximately 206 million people were diagnosed with diabetes in western pacific.

For instance, in May 2022, U.S. Food and Drug Administration (FDA), approved new injectable delivery product, Mounjaro to treat type 2 diabetes. Thus, the rise in prevalence of diabetes has led to the development of advanced insulin delivery systems, which are highly effective to treat diabetes. In addition, growth in prevalence of age-related diseases such as cardiovascular disorders, arthritis, neurodegenerative diseases, and osteoporosis have created a significant demand for effective drug delivery.

For instance, in January 2023, Biogen Inc., one of the global leader in pharmaceutical industry, received U.S. Food and Drug Administration (FDA) approval for LEQEMBI to treat Alzheimer's disease. LEQEMBI is a monoclonal antibody directed intravenous drug delivery medication that effectively treats Alzheimer's disease. Thus, development of new targeted drug delivery and controlled release formulation further contribute toward the market growth. However, stringent regulatory requirements can increase the time, cost, and complexity of new drug delivery technologies and restrain market growth. Furthermore, high costs associated with research and development of new drug delivery negatively impact market growth.

On the other hand, an increase in demand for advanced drug delivery systems is expected to create lucrative opportunities for market growth during the forecast period. This is attributed to the increase in prevalence of chronic diseases, enhanced treatment outcomes, and availability of favorable reimbursement policies for the development of advanced drug delivery systems.

The pharmaceutical drug delivery market is segmented on the basis of route of administration, application, and region. On the basis of route of administration, the market is classified into oral drug delivery, nasal drug delivery, ocular drug delivery, topical drug delivery, and other drug delivery. As per application, the market is categorized into cancer, diabetes, cardiovascular diseases, and others.

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global pharmaceutical drug delivery market are: Bayer AG, Cipla Ltd, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Amgen Inc., Pfizer Inc., Sanofi. Key players operating in the market have adopted product launch and product approval as their key strategies to expand their market share and product portfolio.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pharmaceutical drug delivery market analysis from 2022 to 2032 to identify the prevailing pharmaceutical drug delivery market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the pharmaceutical drug delivery market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global pharmaceutical drug delivery market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Route of Administration

  • Topical drug delivery
  • Other drug delivery
  • Oral drug delivery
  • Nasal drug delivery
  • Ocular drug delivery

By Application

  • Cancer
  • Diabetes
  • Cardiovascular Diseases
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Amgen Inc.
    • Bayer AG
    • Cipla Ltd
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi S.A.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in prevalence of various chronic diseases
      • 3.4.1.2. Technological advancement in drug delivery systems
    • 3.4.2. Restraints
      • 3.4.2.1. Stringent regulatory requirements for the approval of pharmaceutical drug delivery
    • 3.4.3. Opportunities
      • 3.4.3.1. Increase in demand for advanced delivery systems
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Oral drug delivery
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Nasal drug delivery
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Ocular drug delivery
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Topical drug delivery
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country
  • 4.6. Other drug delivery
    • 4.6.1. Key market trends, growth factors and opportunities
    • 4.6.2. Market size and forecast, by region
    • 4.6.3. Market share analysis by country

CHAPTER 5: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Cancer
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Diabetes
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Cardiovascular Diseases
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Others
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country

CHAPTER 6: PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast By Region
  • 6.2. North America
    • 6.2.1. Key trends and opportunities
    • 6.2.2. Market size and forecast, by Route of Administration
    • 6.2.3. Market size and forecast, by Application
    • 6.2.4. Market size and forecast, by country
      • 6.2.4.1. U.S.
      • 6.2.4.1.1. Key market trends, growth factors and opportunities
      • 6.2.4.1.2. Market size and forecast, by Route of Administration
      • 6.2.4.1.3. Market size and forecast, by Application
      • 6.2.4.2. Canada
      • 6.2.4.2.1. Key market trends, growth factors and opportunities
      • 6.2.4.2.2. Market size and forecast, by Route of Administration
      • 6.2.4.2.3. Market size and forecast, by Application
      • 6.2.4.3. Mexico
      • 6.2.4.3.1. Key market trends, growth factors and opportunities
      • 6.2.4.3.2. Market size and forecast, by Route of Administration
      • 6.2.4.3.3. Market size and forecast, by Application
  • 6.3. Europe
    • 6.3.1. Key trends and opportunities
    • 6.3.2. Market size and forecast, by Route of Administration
    • 6.3.3. Market size and forecast, by Application
    • 6.3.4. Market size and forecast, by country
      • 6.3.4.1. Germany
      • 6.3.4.1.1. Key market trends, growth factors and opportunities
      • 6.3.4.1.2. Market size and forecast, by Route of Administration
      • 6.3.4.1.3. Market size and forecast, by Application
      • 6.3.4.2. France
      • 6.3.4.2.1. Key market trends, growth factors and opportunities
      • 6.3.4.2.2. Market size and forecast, by Route of Administration
      • 6.3.4.2.3. Market size and forecast, by Application
      • 6.3.4.3. UK
      • 6.3.4.3.1. Key market trends, growth factors and opportunities
      • 6.3.4.3.2. Market size and forecast, by Route of Administration
      • 6.3.4.3.3. Market size and forecast, by Application
      • 6.3.4.4. Italy
      • 6.3.4.4.1. Key market trends, growth factors and opportunities
      • 6.3.4.4.2. Market size and forecast, by Route of Administration
      • 6.3.4.4.3. Market size and forecast, by Application
      • 6.3.4.5. Spain
      • 6.3.4.5.1. Key market trends, growth factors and opportunities
      • 6.3.4.5.2. Market size and forecast, by Route of Administration
      • 6.3.4.5.3. Market size and forecast, by Application
      • 6.3.4.6. Rest of Europe
      • 6.3.4.6.1. Key market trends, growth factors and opportunities
      • 6.3.4.6.2. Market size and forecast, by Route of Administration
      • 6.3.4.6.3. Market size and forecast, by Application
  • 6.4. Asia-Pacific
    • 6.4.1. Key trends and opportunities
    • 6.4.2. Market size and forecast, by Route of Administration
    • 6.4.3. Market size and forecast, by Application
    • 6.4.4. Market size and forecast, by country
      • 6.4.4.1. Japan
      • 6.4.4.1.1. Key market trends, growth factors and opportunities
      • 6.4.4.1.2. Market size and forecast, by Route of Administration
      • 6.4.4.1.3. Market size and forecast, by Application
      • 6.4.4.2. China
      • 6.4.4.2.1. Key market trends, growth factors and opportunities
      • 6.4.4.2.2. Market size and forecast, by Route of Administration
      • 6.4.4.2.3. Market size and forecast, by Application
      • 6.4.4.3. India
      • 6.4.4.3.1. Key market trends, growth factors and opportunities
      • 6.4.4.3.2. Market size and forecast, by Route of Administration
      • 6.4.4.3.3. Market size and forecast, by Application
      • 6.4.4.4. Australia
      • 6.4.4.4.1. Key market trends, growth factors and opportunities
      • 6.4.4.4.2. Market size and forecast, by Route of Administration
      • 6.4.4.4.3. Market size and forecast, by Application
      • 6.4.4.5. South Korea
      • 6.4.4.5.1. Key market trends, growth factors and opportunities
      • 6.4.4.5.2. Market size and forecast, by Route of Administration
      • 6.4.4.5.3. Market size and forecast, by Application
      • 6.4.4.6. Rest of Asia-Pacific
      • 6.4.4.6.1. Key market trends, growth factors and opportunities
      • 6.4.4.6.2. Market size and forecast, by Route of Administration
      • 6.4.4.6.3. Market size and forecast, by Application
  • 6.5. LAMEA
    • 6.5.1. Key trends and opportunities
    • 6.5.2. Market size and forecast, by Route of Administration
    • 6.5.3. Market size and forecast, by Application
    • 6.5.4. Market size and forecast, by country
      • 6.5.4.1. Brazil
      • 6.5.4.1.1. Key market trends, growth factors and opportunities
      • 6.5.4.1.2. Market size and forecast, by Route of Administration
      • 6.5.4.1.3. Market size and forecast, by Application
      • 6.5.4.2. Saudi Arabia
      • 6.5.4.2.1. Key market trends, growth factors and opportunities
      • 6.5.4.2.2. Market size and forecast, by Route of Administration
      • 6.5.4.2.3. Market size and forecast, by Application
      • 6.5.4.3. South Africa
      • 6.5.4.3.1. Key market trends, growth factors and opportunities
      • 6.5.4.3.2. Market size and forecast, by Route of Administration
      • 6.5.4.3.3. Market size and forecast, by Application
      • 6.5.4.4. Rest of LAMEA
      • 6.5.4.4.1. Key market trends, growth factors and opportunities
      • 6.5.4.4.2. Market size and forecast, by Route of Administration
      • 6.5.4.4.3. Market size and forecast, by Application

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

  • 8.1. F. Hoffmann-La Roche Ltd.
    • 8.1.1. Company overview
    • 8.1.2. Key Executives
    • 8.1.3. Company snapshot
    • 8.1.4. Operating business segments
    • 8.1.5. Product portfolio
    • 8.1.6. Business performance
  • 8.2. GlaxoSmithKline plc
    • 8.2.1. Company overview
    • 8.2.2. Key Executives
    • 8.2.3. Company snapshot
    • 8.2.4. Operating business segments
    • 8.2.5. Product portfolio
    • 8.2.6. Business performance
  • 8.3. Johnson & Johnson
    • 8.3.1. Company overview
    • 8.3.2. Key Executives
    • 8.3.3. Company snapshot
    • 8.3.4. Operating business segments
    • 8.3.5. Product portfolio
    • 8.3.6. Business performance
  • 8.4. Merck & Co., Inc.
    • 8.4.1. Company overview
    • 8.4.2. Key Executives
    • 8.4.3. Company snapshot
    • 8.4.4. Operating business segments
    • 8.4.5. Product portfolio
    • 8.4.6. Business performance
  • 8.5. Novartis AG
    • 8.5.1. Company overview
    • 8.5.2. Key Executives
    • 8.5.3. Company snapshot
    • 8.5.4. Operating business segments
    • 8.5.5. Product portfolio
    • 8.5.6. Business performance
    • 8.5.7. Key strategic moves and developments
  • 8.6. Pfizer Inc.
    • 8.6.1. Company overview
    • 8.6.2. Key Executives
    • 8.6.3. Company snapshot
    • 8.6.4. Operating business segments
    • 8.6.5. Product portfolio
    • 8.6.6. Business performance
  • 8.7. Sanofi S.A.
    • 8.7.1. Company overview
    • 8.7.2. Key Executives
    • 8.7.3. Company snapshot
    • 8.7.4. Operating business segments
    • 8.7.5. Product portfolio
    • 8.7.6. Business performance
  • 8.8. Bayer AG
    • 8.8.1. Company overview
    • 8.8.2. Key Executives
    • 8.8.3. Company snapshot
    • 8.8.4. Operating business segments
    • 8.8.5. Product portfolio
    • 8.8.6. Business performance
  • 8.9. Cipla Ltd
    • 8.9.1. Company overview
    • 8.9.2. Key Executives
    • 8.9.3. Company snapshot
    • 8.9.4. Operating business segments
    • 8.9.5. Product portfolio
    • 8.9.6. Business performance
  • 8.10. Amgen Inc.
    • 8.10.1. Company overview
    • 8.10.2. Key Executives
    • 8.10.3. Company snapshot
    • 8.10.4. Operating business segments
    • 8.10.5. Product portfolio
    • 8.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 02. PHARMACEUTICAL DRUG DELIVERY MARKET FOR ORAL DRUG DELIVERY, BY REGION, 2022-2032 ($BILLION)
  • TABLE 03. PHARMACEUTICAL DRUG DELIVERY MARKET FOR NASAL DRUG DELIVERY, BY REGION, 2022-2032 ($BILLION)
  • TABLE 04. PHARMACEUTICAL DRUG DELIVERY MARKET FOR OCULAR DRUG DELIVERY, BY REGION, 2022-2032 ($BILLION)
  • TABLE 05. PHARMACEUTICAL DRUG DELIVERY MARKET FOR TOPICAL DRUG DELIVERY, BY REGION, 2022-2032 ($BILLION)
  • TABLE 06. PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHER DRUG DELIVERY, BY REGION, 2022-2032 ($BILLION)
  • TABLE 07. GLOBAL PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 08. PHARMACEUTICAL DRUG DELIVERY MARKET FOR CANCER, BY REGION, 2022-2032 ($BILLION)
  • TABLE 09. PHARMACEUTICAL DRUG DELIVERY MARKET FOR DIABETES, BY REGION, 2022-2032 ($BILLION)
  • TABLE 10. PHARMACEUTICAL DRUG DELIVERY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022-2032 ($BILLION)
  • TABLE 11. PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHERS, BY REGION, 2022-2032 ($BILLION)
  • TABLE 12. PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION, 2022-2032 ($BILLION)
  • TABLE 13. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 14. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 15. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($BILLION)
  • TABLE 16. U.S. PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 17. U.S. PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 18. CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 19. CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 20. MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 21. MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 22. EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 23. EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 24. EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($BILLION)
  • TABLE 25. GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 26. GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 27. FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 28. FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 29. UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 30. UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 31. ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 32. ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 33. SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 34. SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 35. REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 36. REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 37. ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 38. ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 39. ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($BILLION)
  • TABLE 40. JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 41. JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 42. CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 43. CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 44. INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 45. INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 46. AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 47. AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 48. SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 49. SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 50. REST OF ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 51. REST OF ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 52. LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 53. LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 54. LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($BILLION)
  • TABLE 55. BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 56. BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 57. SAUDI ARABIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 58. SAUDI ARABIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 59. SOUTH AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 60. SOUTH AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 61. REST OF LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
  • TABLE 62. REST OF LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
  • TABLE 63. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 64. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 65. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 66. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 67. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 68. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 69. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
  • TABLE 70. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 71. JOHNSON & JOHNSON: KEY EXECUTIVES
  • TABLE 72. JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 73. JOHNSON & JOHNSON: PRODUCT SEGMENTS
  • TABLE 74. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
  • TABLE 75. MERCK & CO., INC.: KEY EXECUTIVES
  • TABLE 76. MERCK & CO., INC.: COMPANY SNAPSHOT
  • TABLE 77. MERCK & CO., INC.: PRODUCT SEGMENTS
  • TABLE 78. MERCK & CO., INC.: PRODUCT PORTFOLIO
  • TABLE 79. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 80. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 81. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 82. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 83. NOVARTIS AG: KEY STRATERGIES
  • TABLE 84. PFIZER INC.: KEY EXECUTIVES
  • TABLE 85. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 86. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 87. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 88. SANOFI S.A.: KEY EXECUTIVES
  • TABLE 89. SANOFI S.A.: COMPANY SNAPSHOT
  • TABLE 90. SANOFI S.A.: PRODUCT SEGMENTS
  • TABLE 91. SANOFI S.A.: PRODUCT PORTFOLIO
  • TABLE 92. BAYER AG: KEY EXECUTIVES
  • TABLE 93. BAYER AG: COMPANY SNAPSHOT
  • TABLE 94. BAYER AG: PRODUCT SEGMENTS
  • TABLE 95. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 96. CIPLA LTD: KEY EXECUTIVES
  • TABLE 97. CIPLA LTD: COMPANY SNAPSHOT
  • TABLE 98. CIPLA LTD: PRODUCT SEGMENTS
  • TABLE 99. CIPLA LTD: PRODUCT PORTFOLIO
  • TABLE 100. AMGEN INC.: KEY EXECUTIVES
  • TABLE 101. AMGEN INC.: COMPANY SNAPSHOT
  • TABLE 102. AMGEN INC.: PRODUCT SEGMENTS
  • TABLE 103. AMGEN INC.: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN PHARMACEUTICAL DRUG DELIVERY MARKET (2023-2032)
  • FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. LOW THREAT OF NEW ENTRANTS
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALPHARMACEUTICAL DRUG DELIVERY MARKET
  • FIGURE 10. PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR ORAL DRUG DELIVERY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR NASAL DRUG DELIVERY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR OCULAR DRUG DELIVERY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR TOPICAL DRUG DELIVERY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHER DRUG DELIVERY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR CANCER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR DIABETES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. PHARMACEUTICAL DRUG DELIVERY MARKET BY REGION, 2022
  • FIGURE 22. U.S. PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 23. CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 24. MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 25. GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 26. FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 27. UK PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 28. ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 29. SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 30. REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 31. JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 32. CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 33. INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 34. AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 35. SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 36. REST OF ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 37. BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 38. SAUDI ARABIA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 39. SOUTH AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 40. REST OF LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
  • FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 44. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 45. COMPETITIVE DASHBOARD
  • FIGURE 46. COMPETITIVE HEATMAP: PHARMACEUTICAL DRUG DELIVERY MARKET
  • FIGURE 47. TOP PLAYER POSITIONING, 2022
  • FIGURE 48. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 49. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 50. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 52. GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 53. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 55. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 56. MERCK & CO., INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 57. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 58. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 59. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 60. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 61. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 62. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 63. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 64. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 65. SANOFI S.A.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 66. SANOFI S.A.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 67. SANOFI S.A.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 68. BAYER AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 69. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 70. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 71. CIPLA LTD: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 72. CIPLA LTD: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 73. CIPLA LTD: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 74. AMGEN INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 75. AMGEN INC.: REVENUE SHARE BY REGION, 2022 (%)